Daniel Raskas
Known title: DirectorCIK: 0001306860
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Danaher Expands AI Integration in Scientific Research. Danaher has announced a partnership to integrate AI into scientific research workflows, a move that could enhance its diagnostic and drug discovery capabilities. With Q3 earnings approaching, investors are watching to see if this strategic shift supports the company's recovery narrative. The stock currently trades near its 52-week high, reflecting optimism about these operational improvements.
Transaction History
| NVST | ▲ Buy | Grant | 9,330 | $0 | 5/19/2026 | View on chart |
| NVST | ▲ Buy | Grant | 10,450 | $0 | 6/10/2025 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 4,701 | $1.0M | 2/3/2025 | View on chart |
| DHR | ▼ Sell | Open Market | 26,318 | $6.2M | 11/26/2024 | View on chart |
| DHR | ▲ Buy | Option Exercise | 26,318 | $1.5M | 11/26/2024 | View on chart |
| DHR | ▼ Sell | Open Market | 8,370 | $2.0M | 11/25/2024 | View on chart |
| DHR | ▼ Sell | Open Market | 14,507 | $3.9M | 7/25/2024 | View on chart |
| NVST | ▲ Buy | Grant | 10,085 | $0 | 5/21/2024 | View on chart |
| DHR | ▼ Sell | Gift | 591 | $0 | 2/26/2024 | View on chart |
| DHR | ▲ Buy | Option Exercise | 23,757 | $1.4M | 2/26/2024 | View on chart |
| DHR | ▼ Sell | Open Market | 23,757 | $6.0M | 2/26/2024 | View on chart |
| DHR | ▲ Buy | Grant | 3,471 | $0 | 2/21/2024 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 5,984 | $1.5M | 2/1/2024 | View on chart |
| DHR | ▼ Sell | Gift | 385 | $0 | 7/28/2023 | View on chart |
| DHR | ▲ Buy | Option Exercise | 11,213 | $636K | 7/28/2023 | View on chart |
| DHR | ▼ Sell | Open Market | 11,213 | $2.9M | 7/28/2023 | View on chart |
| DHR | ▼ Sell | Open Market | 19,847 | $4.5M | 5/31/2023 | View on chart |
| DHR | ▲ Buy | Option Exercise | 19,847 | $1.1M | 5/31/2023 | View on chart |
| NVST | ▲ Buy | Grant | 5,425 | $0 | 5/23/2023 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 510 | $127K | 2/24/2023 | View on chart |
| DHR | ▲ Buy | Grant | 10,440 | $0 | 2/22/2023 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 2,486 | $665K | 2/1/2023 | View on chart |
| DHR | ▼ Sell | Gift | 412 | $0 | 11/4/2022 | View on chart |
| NVST | ▲ Buy | Grant | 4,435 | $0 | 5/24/2022 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 994 | $270K | 2/24/2022 | View on chart |
| DHR | ▲ Buy | Grant | 12,750 | $0 | 2/23/2022 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 2,359 | $678K | 2/1/2022 | View on chart |
| DHR | ▼ Sell | Open Market | 12,294 | $4.0M | 11/30/2021 | View on chart |
| DHR | ▲ Buy | Option Exercise | 12,294 | $567K | 11/30/2021 | View on chart |
| DHR | ▲ Buy | Option Exercise | 12,300 | $567K | 11/26/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 12,300 | $4.0M | 11/26/2021 | View on chart |
| DHR | ▼ Sell | Gift | 306 | $0 | 8/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Piper Sandler cuts Envista price target to $26, maintains Neutral
Piper Sandler recently lowered its price target for Envista Holdings to $26 while keeping a Neutral stance. This move aligns with the stock's current trading level near its 52-week low of $18.77. The company has also scheduled its third-quarter 2026 earnings call, which will provide updated financial insights.
Piper Sandler cuts Envista price target to $26, maintains Neutral. Piper Sandler recently lowered its price target for Envista Holdings to $26 while keeping a Neutral stance. This move aligns with the stock's current trading level near its 52-week low of $18.77. The company has also scheduled its third-quarter 2026 earnings call, which will provide updated financial insights.